c-KIT oncogene expression in PRKAR1A-mutant adrenal cortex

in Endocrine-Related Cancer
View More View Less
  • 1 Section on Genetics and Endocrinology (SEGEN), Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland, USA

Correspondence should be addressed to F R Faucz: fabio.faucz@nih.gov
Restricted access

Protein kinase A (PKA) regulatory subunit type 1A (PRKAR1A) defects lead to primary pigmented nodular adrenocortical disease (PPNAD). The KIT protooncogene (c-KIT) is not known to be expressed in the normal adrenal cortex (AC). In this study, we investigated the expression of c-KIT and its ligand, stem cell factor (SCF), in PPNAD and other cortisol-producing tumors of the adrenal cortex. mRNA and protein expression, by qRT-PCR, immunohistochemistry (IHC) and immunoblotting (IB), respectively, were studied. We then tested c-KIT and SCF responses to PRKAR1A introduction and PKA stimulation in adrenocortical cell lines CAR47 and H295R, which were also treated with the KIT inhibitor, imatinib mesylate (IM). Mice xenografted with H295R cells were treated with IM. There was increased c-KIT mRNA expression in PPNAD; IHC showed KIT and SCF immunoreactivity within certain nodular areas in PPNAD. IB data was consistent with IHC and mRNA data. PRKAR1A-deficient CAR47 cells expressed c-KIT; this was enhanced by forskolin and lowered by PRKAR1A reintroduction. Knockdown of PKA’s catalytic subunit (PRKACA) by siRNA reduced c-KIT levels. Treatment of the CAR47 cells with IM resulted in reduced cell viability, growth arrest, and apoptosis. Treatment with IM of mice xenografted with H295 cells inhibited further tumor growth. We conclude that c-KIT is expressed in PPNAD, an expression that appears to be dependent on PRKAR1A and/or PKA activity. In a human adrenocortical cell line and its xenografts in mice, c-KIT inhibition decreased growth, suggesting that c-KIT inhibitors may be a reasonable alternative therapy to be tested in PPNAD, when other treatments are not optimal.

Supplementary Materials

    • Supplementary table1. Samples and mutations in PRKAR1A
    • Supplementary table 2. Oligonucleotide sequence for exons 8, 9, 10, 11, 13, and 17 amplification in human c-KIT with their predicted sizes
    • Supplementary Figure 1

 

      Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 189 189 189
Full Text Views 12 12 12
PDF Downloads 4 4 4
  • Almeida MQ, Harran M, Bimpaki EI, Hsiao HP, Horvath A, Cheadle C, Watkins T, Nesterova M & Stratakis CA 2011 Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. Journal of Clinical Endocrinology and Metabolism 96 E728E738. (https://doi.org/10.1210/jc.2010-2420)

    • Search Google Scholar
    • Export Citation
  • Angelousi A, Szarek E, Shram V, Kebebew E, Quezado M & Stratakis CA 2017 Lipofuscin accumulation in cortisol-producing adenomas with and without PRKACA mutations. Hormone and Metabolic Research 49 786792. (https://doi.org/10.1055/s-0043-116385)

    • Search Google Scholar
    • Export Citation
  • Azevedo MF, Horvath A, Bornstein ER, Almeida MQ, Xekouki P, Faucz FR, Gourgari E, Nadella K, Remmers EF, Quezado M, 2013 Cyclic AMP and c-KIT signaling in familial testicular germ cell tumor predisposition. Journal of Clinical Endocrinology and Metabolism 98 E1393E1400. (https://doi.org/10.1210/jc.2012-2838)

    • Search Google Scholar
    • Export Citation
  • Bayne S, Jones ME, Li H, Pinto AR, Simpson ER & Liu JP 2008 Estrogen deficiency leads to telomerase inhibition, telomere shortening and reduced cell proliferation in the adrenal gland of mice. Cell Research 18 11411150. (https://doi.org/10.1038/cr.2008.291)

    • Search Google Scholar
    • Export Citation
  • Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S, Volante M, Daffara F, Generali D, 2012 Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. European Journal of Endocrinology 166 451458. (https://doi.org/10.1530/EJE-11-0918)

    • Search Google Scholar
    • Export Citation
  • Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, 2014 Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. New England Journal of Medicine 370 10191028. (https://doi.org/10.1056/NEJMoa1310359)

    • Search Google Scholar
    • Export Citation
  • Boyer HG, Wils J, Renouf S, Arabo A, Duparc C, Boutelet I, Lefebvre H & Louiset E 2017 Dysregulation of aldosterone secretion in mast cell-deficient mice. Hypertension 70 12561263. (https://doi.org/10.1161/HYPERTENSIONAHA.117.09746)

    • Search Google Scholar
    • Export Citation
  • Bram Z, Louiset E, Ragazzon B, Renouf S, Wils J, Duparc C, Boutelet I, Rizk-Rabin M, Libé R, Young J, 2016 PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease. JCI Insight 1 e87958. (https://doi.org/10.1172/jci.insight.87958)

    • Search Google Scholar
    • Export Citation
  • Duparc C, Moreau L, Dzib JF, Boyer HG, Tetsi Nomigni M, Boutelet I, Boulkroun S, Mukai K, Benecke AG, Amar L, 2015 Mast cell hyperplasia is associated with aldosterone hypersecretion in a subset of aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 100 E550E560. (https://doi.org/10.1210/jc.2014-3660)

    • Search Google Scholar
    • Export Citation
  • Gu Y, Runyan C, Shoemaker A, Surani A & Wylie C 2009 Steel factor controls primordial germ cell survival and motility from the time of their specification in the allantois, and provides a continuous niche throughout their migration. Development 136 12951303. (https://doi.org/10.1242/dev.030619)

    • Search Google Scholar
    • Export Citation
  • Hannah-Shmouni F & Stratakis CA 2020 A gene-based classification of primary adrenocortical hyperplasias. Hormone and Metabolic Research 52 133141. (https://doi.org/10.1055/a-1107-2972)

    • Search Google Scholar
    • Export Citation
  • Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP, 2006a A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nature Genetics 38 794800. (https://doi.org/10.1038/ng1809)

    • Search Google Scholar
    • Export Citation
  • Horvath A, Mathyakina L, Vong Q, Baxendale V, Pang AL, Chan WY & Stratakis CA 2006b Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. Journal of Clinical Endocrinology and Metabolism 91 584596. (https://doi.org/10.1210/jc.2005-1301)

    • Search Google Scholar
    • Export Citation
  • Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libé R, Remmers E, René-Corail F, Faucz FR, 2010 Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Human Mutation 31 369379. (https://doi.org/10.1002/humu.21178)

    • Search Google Scholar
    • Export Citation
  • Kim JS, Kubota H, Kiuchi Y, Doi K & Saegusa J 1997 Subcapsular cell hyperplasia and mast cell infiltration in the adrenal cortex of mice: comparative study in 7 inbred strains. Experimental Animals 46 303306. (https://doi.org/10.1538/expanim.46.303)

    • Search Google Scholar
    • Export Citation
  • Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS & Stratakis CA 2000 Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics 26 8992. (https://doi.org/10.1038/79238)

    • Search Google Scholar
    • Export Citation
  • Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, 2020 Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. Journal of Clinical Endocrinology and Metabolism 105 dgz318. (https://doi.org/10.1210/clinem/dgz318)

    • Search Google Scholar
    • Export Citation
  • Le Mestre J, Duparc C, Reznik Y, Bonnet-Serrano F, Touraine P, Chabre O, Young J, Suzuki M, Sibony M, Gobet F, 2019 Illicit upregulation of serotonin signaling pathway in adrenals of patients with high plasma or intra-adrenal ACTH levels. Journal of Clinical Endocrinology and Metabolism 104 49674980. (https://doi.org/10.1210/jc.2019-00425)

    • Search Google Scholar
    • Export Citation
  • Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, Seto M, Seito T, Sugiura T, Ariyoshi Y & Takahashi T 1993 Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. American Journal of Pathology 142 339346.

    • Search Google Scholar
    • Export Citation
  • Nesterova M, Bossis I, Wen F, Horvath A, Matyakhina L & Stratakis CA 2008 An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type allele and other protein kinase A subunits. Journal of Clinical Endocrinology and Metabolism 93 565571. (https://doi.org/10.1210/jc.2007-1902)

    • Search Google Scholar
    • Export Citation
  • O’Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S & Fojo T 2014 The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism 99 12911297. (https://doi.org/10.1210/jc.2013-2298)

    • Search Google Scholar
    • Export Citation
  • Patterson EE, Holloway AK, Weng J, Fojo T & Kebebew E 2011 MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117 16301639. (https://doi.org/10.1002/cncr.25724)

    • Search Google Scholar
    • Export Citation
  • Rothschild G, Sottas CM, Kissel H, Agosti V, Manova K, Hardy MP & Besmer P 2003 A role for kit receptor signaling in Leydig cell steroidogenesis. Biology of Reproduction 69 925932. (https://doi.org/10.1095/biolreprod.102.014548)

    • Search Google Scholar
    • Export Citation
  • Stratakis CA, Carney JA, Kirschner LS, Willenberg HS, Brauer S, Ehrhart-Bornstein M & Bornstein SR 1999 Synaptophysin immunoreactivity in primary pigmented nodular adrenocortical disease: neuroendocrine properties of tumors associated with Carney complex. Journal of Clinical Endocrinology and Metabolism 84 11221128. (https://doi.org/10.1210/jcem.84.3.5549)

    • Search Google Scholar
    • Export Citation
  • Theoharides TC, Bondy PK, Tsakalos ND & Askenase PW 1982 Differential release of serotonin and histamine from mast cells. Nature 297 229231. (https://doi.org/10.1038/297229a0)

    • Search Google Scholar
    • Export Citation
  • Willenberg HS, Stratakis CA, Marx C, Ehrhart-Bornstein M, Chrousos GP & Bornstein SR 1998 Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing’s syndrome. New England Journal of Medicine 339 2731. (https://doi.org/10.1056/NEJM199807023390105)

    • Search Google Scholar
    • Export Citation
  • Zhang PJ, Genega EM, Tomaszewski JE, Pasha TL & Livolsi VA 2003 The role of calretinin, inhibin, melan-A, BCL-2, and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Modern Pathology 16 591597. (https://doi.org/10.1097/01.MP.0000073134.60541.E8)

    • Search Google Scholar
    • Export Citation